about
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerHypercalcemia of Malignancy: An Update on Pathogenesis and ManagementBone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women's health practiceMedication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic ApproachesCan denosumab be a substitute, competitor, or complement to bisphosphonates?Denosumab: A bone antiresorptive drugManagement of atypical femoral fracture: a scoping review and comprehensive algorithm.Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home settingAdvances in osteoclast biology reveal potential new drug targets and new roles for osteoclastsAdvances in the regulation of osteoclasts and osteoclast functions.Neurological Recovery in Two Patients with Cauda Equina Syndrome Secondary to L5 Lumbar Spine Giant Cell Tumour after Treatment with Denosumab without Surgery.Response of an aggressive periosteal aneurysmal bone cyst (ABC) of the radius to denosumab therapy.Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal womenDisease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature.Targeting collagen for diagnostic imaging and therapeutic delivery.Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience.Can we prevent BRCA1-associated breast cancer by RANKL inhibition?Denosumab for treatment of immobilization-related hypercalcemia in a patient with end-stage renal disease.Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains.A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.Inhibition of receptor activator of nuclear factor kappa-B ligand pathway for the management of aggressive osteosarcoma.Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.Exercise and bone health across the lifespan.The prevention of postmenopausal osteoporotic fractures: results of the Health Technology Assessment of a new antiosteoporotic drug.[Metabolic disorders as paraneoplastic syndromes].Mucolipidosis type III, a series of adult patientsOsteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
P2860
Q26746212-B4C967E7-4873-4945-A4F6-A828F5FACEB7Q26771719-FF7B7780-0107-48C1-9DF4-61BFF9ACDC02Q28066185-504011FB-7AC1-4AE5-BB78-6DCE7EB2B7F2Q28072449-1A2AD625-2F21-4386-8CDF-9A69CA769D01Q33567830-6946A7AC-319A-4550-987B-E945D462883BQ34980675-39D3C2BE-903E-4C79-9882-C8C5CAC30672Q36027214-3DC8416B-237F-4DF1-A520-71897CD1CB8BQ36665368-44AC12A4-2490-4361-8A39-997A99E8D4F5Q36733053-FE1871AC-6277-4F88-9094-FF9F7262A9EFQ37177840-D5C71FD0-3BC2-4720-96FE-DA47607F77ADQ37368567-64810B59-5C16-43BA-AD67-8D305ED77ED3Q37513025-96383957-4B60-465E-B033-43C3324FFC21Q37740752-98EA245E-5A75-4A93-A0D6-755F2052DCA6Q38698132-23EC16BA-EF85-44EC-B4EF-94D1FBAB6C34Q38698660-22602A0C-B2EF-450B-8499-E0051BBA014BQ38845259-3B5F7AB6-D613-4FDB-9C9F-E71C82AE8195Q38991293-86B3B058-387F-4AB7-A0F4-0E654F3E0AF7Q40210827-1AA04591-3300-4246-8F96-44A3DEFFCC97Q41044574-7382BC3C-E46C-45F0-9446-02E32AA51226Q41240776-CFAF3993-603D-47D9-BF7E-FAA6B726D7E4Q42330816-8702A147-756E-44CC-A494-3CA56F6423B9Q42908395-1CC1A195-820F-43D8-9178-7453E8C94D9EQ47100094-0ACB0246-2FEC-4A14-8B0D-76DC235B0EB5Q48322047-3DC3012F-EAB4-4AD8-8E8E-7F138371EFB9Q49581415-4CE3EA0F-4D21-400A-AADD-5F436053E45BQ57164826-FDE96311-2A56-40A7-84B4-9924D55AC461Q58790080-9FDAA32C-C9E4-435E-8FDE-8134BF15A6A8
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Denosumab: mechanism of action and clinical outcomes
@ast
Denosumab: mechanism of action and clinical outcomes
@en
Denosumab: mechanism of action and clinical outcomes
@nl
type
label
Denosumab: mechanism of action and clinical outcomes
@ast
Denosumab: mechanism of action and clinical outcomes
@en
Denosumab: mechanism of action and clinical outcomes
@nl
prefLabel
Denosumab: mechanism of action and clinical outcomes
@ast
Denosumab: mechanism of action and clinical outcomes
@en
Denosumab: mechanism of action and clinical outcomes
@nl
P2093
P2860
P921
P3181
P356
P1476
Denosumab: mechanism of action and clinical outcomes
@en
P2093
D. A. Hanley
J. D. Adachi
P2860
P304
P3181
P356
10.1111/IJCP.12022
P407
P5008
P577
2012-12-01T00:00:00Z